Your browser is no longer supported. Please, upgrade your browser.
Settings
UTHR United Therapeutics Corporation daily Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E13.96 EPS (ttm)8.58 Insider Own0.10% Shs Outstand43.36M Perf Week-1.85%
Market Cap5.19B Forward P/E11.04 EPS next Y10.85 Insider Trans-49.28% Shs Float42.71M Perf Month-0.84%
Income394.70M PEG- EPS next Q3.87 Inst Own94.00% Short Float14.56% Perf Quarter-7.83%
Sales1.63B P/S3.18 EPS this Y19.90% Inst Trans-0.03% Short Ratio11.16 Perf Half Y-1.07%
Book/sh39.98 P/B3.00 EPS next Y2.35% ROA16.00% Target Price124.00 Perf Year2.47%
Cash/sh25.72 P/C4.66 EPS next 5Y- ROE20.80% 52W Range110.90 - 169.89 Perf YTD-16.49%
Dividend- P/FCF7.49 EPS past 5Y33.00% ROI38.40% 52W High-29.50% Beta1.38
Dividend %- Quick Ratio1.70 Sales past 5Y16.60% Gross Margin94.80% 52W Low8.01% ATR2.95
Employees750 Current Ratio1.90 Sales Q/Q7.80% Oper. Margin44.00% RSI (14)43.48 Volatility1.82% 2.34%
OptionableYes Debt/Eq0.14 EPS Q/Q-128.40% Profit Margin24.20% Rel Volume0.54 Prev Close120.51
ShortableYes LT Debt/Eq0.00 EarningsOct 26 BMO Payout0.00% Avg Volume557.26K Price119.78
Recom3.20 SMA20-0.11% SMA50-4.50% SMA200-10.63% Volume301,811 Change-0.61%
Apr-27-17Reiterated Wedbush Outperform $229 → $213
Mar-30-17Initiated UBS Sell $112
Mar-16-17Initiated Credit Suisse Underperform
Mar-06-17Downgrade Jefferies Hold → Underperform
Feb-23-17Downgrade Ladenburg Thalmann Buy → Neutral
Jan-19-17Downgrade Standpoint Research Buy → Hold
Dec-15-16Initiated Oppenheimer Outperform
Oct-28-16Upgrade Ladenburg Thalmann Neutral → Buy
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Jul-31-15Reiterated Argus Buy $205 → $200
Jul-29-15Reiterated RBC Capital Mkts Sector Perform $160 → $175
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Oct-13-17 08:06AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Oct-09-17 10:39AM  United Therapeuticss Net Profit Margins Are Expected to Narrow Market Realist
09:13AM  Why United Therapeutics Revenue May Rise in 2017 Market Realist
08:06AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
07:44AM  Analysts Recommendations for United Therapeutics Market Realist
Sep-21-17 09:35AM  Is United Therapeutics a Great Stock for Value Investors? Zacks
Sep-19-17 09:00AM  Martine Rothblatt is Featured in Forbes Magazine's Special Centennial Issue as one of The World's 100 Greatest Living Business Minds PR Newswire
Sep-18-17 08:06AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Sep-15-17 08:03AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Sep-13-17 08:02AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Sep-12-17 08:02AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Sep-11-17 10:43AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : September 11, 2017 Capital Cube
08:02AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Sep-08-17 01:23PM  Here's Why United Therapeutics Sank as Much as 10.8% Today Motley Fool -9.51%
Sep-07-17 08:00PM  United Therapeutics Announces FREEDOM-EV Study Of Orenitram® To Continue As Planned Following Interim Analysis PR Newswire
Sep-01-17 10:05AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : September 1, 2017 Capital Cube
07:37AM  How United Therapeutics Adcirca and Tyvaso Are Positioned in 3Q17 Market Realist
07:36AM  Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders Market Realist
Aug-31-17 10:37AM  How United Therapeutics Remodulin and Tyvaso Are Performing Market Realist
10:36AM  Technology Platforms and Research Programs Drive LGNDs Partnerships Market Realist
09:08AM  How Did United Therapeutics Orenitram and Unituxin Perform in 2Q17? Market Realist
07:38AM  How Did United Therapeutics Perform in 2Q17? Market Realist
Aug-30-17 04:43PM  What Analysts Recommend for United Therapeutics in August 2017 Market Realist
Aug-29-17 08:06AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Aug-28-17 09:51PM  United Therapeutics Corp. Value Analysis (NASDAQ:UTHR) : August 29, 2017 Capital Cube
Aug-24-17 08:01AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Aug-22-17 08:04AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Aug-21-17 04:48PM  Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform PR Newswire
04:22PM  Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform PR Newswire
09:03AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : August 21, 2017 Capital Cube
Aug-15-17 02:03PM  United Therapeutics, Mayo Clinic to build lung restoration facility in Florida American City Business Journals
Aug-12-17 07:00PM  Edited Transcript of UTHR earnings conference call or presentation 27-Jul-17 1:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 07:10PM  ETFs with exposure to United Therapeutics Corp. : August 11, 2017 Capital Cube
08:01AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
Aug-10-17 02:01PM  Stealthy Viruses Take Center Stage In Efforts To Transplant Pig Organs Into People Forbes
09:44AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : August 10, 2017 Capital Cube
Aug-09-17 08:04AM  See what the IHS Markit Score report has to say about United Therapeutics Corp. Markit
06:00AM  United Therapeutics Corporation To Present At 2017 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-04-17 06:04PM  Analysts say a United Therapeutics sale is premature American City Business Journals +7.76%
05:08PM  United Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk InvestorPlace
12:15PM  Gilead Could Be Making An Acquisition But It's Not What You Think Investor's Business Daily
10:43AM  Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring TheStreet.com
08:47AM  United Therapeutics Corp. stock surges 9% on report of possible bids for company MarketWatch
08:31AM  Morning Movers: Viacom Tumbles on Earnings; United Therapeutics Soars Barrons.com
Aug-03-17 03:46PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of United Therapeutix Corporation (UTHR) on Behalf of Shareholders Business Wire
Aug-02-17 10:30AM  INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of United Therapeutics Corporation Business Wire
06:46AM  Lifshitz & Miller LLP Announces Investigation of EZCORP, Inc., Flowserve Corporation, Halliburton Company, NCI, Inc., Parkway, Inc., United Therapeutics Corporation and ViewRay, Inc. PR Newswire
Jul-31-17 07:24PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of United Therapeutics Corporation and Encourages Investors with Losses to Contact the Firm Business Wire
05:30PM  UNITED THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In United Therapeutics Corporation To Contact The Firm Business Wire
Jul-28-17 01:35PM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
12:50PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of United Therapeutics Corporation Business Wire
11:14AM  UTHR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of United Therapeutics Corporation Business Wire
10:57AM  United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top Zacks
10:09AM  Harwood Feffer LLP Announces Investigation of United Therapeutics Corporation PR Newswire
10:01AM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of United Therapeutics Corporation Business Wire
09:53AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of United Therapeutics Corporation -- UTHR Business Wire
09:42AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : July 28, 2017 Capital Cube
08:13AM  United Therapeutics would have had its strongest quarter ever. Except for this. American City Business Journals
02:04AM  [$$] United Therapeutics in Settlement Talks With Justice Department The Wall Street Journal
Jul-27-17 09:37PM  UNITED THERAPEUTICS CORPORATION (UTHR) INVESTOR ALERT: Legal Investigation for Potential Securities Law Violations Business Wire
07:28PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of United Therapeutics Corporation and Encourages Investors with Losses to Contact the Firm Business Wire
06:52PM  UNITED THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In United Therapeutics Corporation To Contact The Firm PR Newswire
05:36PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of United Therapeutics Corporation Business Wire
05:30PM  Bragar Eagel & Squire, P.C. Is Investigating United Therapeutics Corporation (UTHR) on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
04:36PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of United Therapeutics Corporation (UTHR) PR Newswire
04:29PM  Biotech Fever Cools As These Players Dip On Longer-Term Views Investor's Business Daily
04:22PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of United Therapeutics Corporation Business Wire
04:21PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - (UTHR) ACCESSWIRE
04:17PM  United Therapeutics reports 2Q loss Associated Press
04:09PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against United Therapeutics Corporation - UTHR Business Wire
03:21PM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of United Therapeutics Corporation Investors Business Wire
01:59PM  [$$] United Therapeutics in Settlement Talks With Justice Department The Wall Street Journal
10:32AM  United Therapeutics, DOJ in Possible Settlement Over Drug Contributions TheStreet.com
06:00AM  United Therapeutics Corporation Reports Second Quarter 2017 Financial Results PR Newswire
Jul-25-17 09:05AM  10 Ben Graham-Inspired Stocks For Value's Eventual Turn Forbes
Jul-21-17 12:30PM  United Therapeutics Corporation to Report Second Quarter 2017 Financial Results Before The Market Opens on Thursday, July 27, 2017 PR Newswire
Jul-19-17 10:56AM  Upcoming Catalysts Could Boost United Therapeutics: OpCo Barrons.com
Jul-12-17 09:30AM  E*Trade Financial, Statoil, Arena Pharmaceuticals, Johnson & Johnson and United Therapeutics highlighted as Zacks Bull and Bear of the Day Zacks
Jul-07-17 05:44PM  7 of the Worst-Performing Stocks in Gurus' Portfolios GuruFocus.com
Jul-04-17 10:37AM  What Analysts Recommend for United Therapeutics in June 2017 Market Realist
09:16AM  Cardiome's Partner SteadyMed Submits NDA for PAH Injection Zacks
09:08AM  Adcirca May Witness Gradual Decline in Revenues Market Realist
07:38AM  United Therapeutics Orenitram May Show Revenue Growth in 2017 Market Realist
Jul-03-17 10:39AM  What Can We Expect from United Therapeutics Tyvaso in 2017? Market Realist
09:10AM  How Is United Therapeutics Remodulin Positioned in 2017? Market Realist
07:42AM  How United Therapeutics Is Expected to Perform in 2017 Market Realist
Jun-24-17 12:15AM  [$$] Biotech Blazes Higher Barrons.com
Jun-20-17 06:06PM  Argan and Sturm Ruger Show High Profit and Low Debt GuruFocus.com
Jun-14-17 01:20PM  Silver Spring tissue regeneration company raises $12 million American City Business Journals
Jun-09-17 09:38AM  Your first trade for Friday, June 9 CNBC
Jun-08-17 05:59PM  Fast Money final trades: KSU, SNAP, and more CNBC Videos
Jun-07-17 05:39PM  Here's how the founder of X Prize says you can invest in ... CNBC Videos
Jun-02-17 02:36PM  ETFs with exposure to United Therapeutics Corp. : June 2, 2017 Capital Cube
08:42AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : June 2, 2017 Capital Cube
May-31-17 06:00AM  United Therapeutics Corporation To Present At Jefferies 2017 Global Healthcare Conference PR Newswire
May-19-17 06:50AM  United Therapeutics reworks deal ahead of a key patent's expiration American City Business Journals
May-16-17 08:15AM  Blog Coverage: Ionis Pharma Reported Positive Phase III Results in Patients with Familial Amyloid Polyneuropathy Accesswire
May-15-17 04:50PM  ETFs with exposure to United Therapeutics Corp. : May 15, 2017 Capital Cube
May-12-17 08:30AM  SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-02-17 04:48PM  ETFs with exposure to United Therapeutics Corp. : May 2, 2017 Capital Cube
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & CEOOct 12Option Exercise30.7591428,106677,066Oct 16 08:09 AM
ROTHBLATT MARTINE AChairman & CEOOct 12Option Exercise30.751,26338,8372,332Oct 16 08:09 AM
ROTHBLATT MARTINE AChairman & CEOOct 12Sale120.201,263151,8131,069Oct 16 08:09 AM
MAHON PAUL AEVP & General CounselOct 05Option Exercise57.156,000342,90041,426Oct 06 04:09 PM
ROTHBLATT MARTINE AChairman & CEOOct 05Option Exercise30.751,25638,6222,325Oct 06 04:14 PM
ROTHBLATT MARTINE AChairman & CEOOct 05Option Exercise30.7592028,290676,152Oct 06 04:14 PM
CAUSEY CHRISTOPHERDirectorOct 05Sale122.0058070,7602,715Oct 06 04:12 PM
ROTHBLATT MARTINE AChairman & CEOOct 05Sale122.981,256154,4591,069Oct 06 04:14 PM
ROTHBLATT MARTINE AChairman & CEOSep 28Option Exercise30.7591228,044675,232Sep 29 04:01 PM
ROTHBLATT MARTINE AChairman & CEOSep 28Option Exercise30.751,26538,8992,334Sep 29 04:01 PM
ROTHBLATT MARTINE AChairman & CEOSep 28Sale119.701,265151,4161,069Sep 29 04:01 PM
ROTHBLATT MARTINE AChairman & CEOSep 21Option Exercise30.7590227,737674,320Sep 22 08:04 AM
ROTHBLATT MARTINE AChairman & CEOSep 21Option Exercise30.751,27439,1762,343Sep 22 08:04 AM
MAHON PAUL AEVP & General CounselSep 21Option Exercise57.156,000342,90041,426Sep 22 04:47 PM
ROTHBLATT MARTINE AChairman & CEOSep 21Sale116.071,274147,8681,069Sep 22 08:04 AM
ROTHBLATT MARTINE AChairman & CEOSep 14Option Exercise30.7591928,259673,418Sep 15 04:08 PM
ROTHBLATT MARTINE AChairman & CEOSep 14Option Exercise30.751,25838,6842,327Sep 15 04:08 PM
ROTHBLATT MARTINE AChairman & CEOSep 14Sale122.081,258153,5751,069Sep 15 04:08 PM
ROTHBLATT MARTINE AChairman & CEOSep 07Option Exercise30.7594429,028672,499Sep 08 05:51 PM
ROTHBLATT MARTINE AChairman & CEOSep 07Option Exercise30.751,23237,8842,301Sep 08 05:51 PM
MAHON PAUL AEVP & General CounselSep 07Option Exercise57.156,000342,90041,426Sep 08 05:55 PM
CAUSEY CHRISTOPHERDirectorSep 07Option Exercise54.7775041,0784,045Sep 08 05:53 PM
CAUSEY CHRISTOPHERDirectorSep 07Sale134.4858077,9983,295Sep 07 05:34 PM
ROTHBLATT MARTINE AChairman & CEOSep 07Sale133.321,232164,2561,069Sep 08 05:51 PM
ROTHBLATT MARTINE AChairman & CEOAug 31Option Exercise30.751,23537,9762,304Sep 01 05:09 PM
ROTHBLATT MARTINE AChairman & CEOAug 31Option Exercise30.7594228,967671,555Sep 01 05:09 PM
ROTHBLATT MARTINE AChairman & CEOAug 31Sale130.491,235161,1561,069Sep 01 05:09 PM
ROTHBLATT MARTINE AChairman & CEOAug 24Option Exercise30.751,23838,0692,307Aug 25 04:06 PM
ROTHBLATT MARTINE AChairman & CEOAug 24Option Exercise30.7593828,844670,613Aug 25 04:06 PM
ROTHBLATT MARTINE AChairman & CEOAug 24Sale130.651,238161,7391,069Aug 25 04:06 PM
MAHON PAUL AEVP & General CounselAug 17Option Exercise57.156,000342,90041,426Aug 18 04:20 PM
ROTHBLATT MARTINE AChairman & CEOAug 17Option Exercise30.751,23537,9762,304Aug 17 04:49 PM
ROTHBLATT MARTINE AChairman & CEOAug 17Option Exercise30.7594228,967669,675Aug 17 04:49 PM
ROTHBLATT MARTINE AChairman & CEOAug 17Sale131.951,235162,9621,069Aug 17 04:49 PM
ROTHBLATT MARTINE AChairman & CEOAug 10Option Exercise30.752,17666,9123,245Aug 11 08:00 AM
ROTHBLATT MARTINE AChairman & CEOAug 10Option Exercise30.7593028,598668,733Aug 11 08:00 AM
ROTHBLATT MARTINE AChairman & CEOAug 10Sale127.112,176276,5871,069Aug 11 08:00 AM
DWEK RAYMONDDirectorAug 04Option Exercise51.772,000103,5402,000Aug 07 08:45 AM
CAUSEY CHRISTOPHERDirectorAug 03Option Exercise54.7775041,0784,625Aug 07 08:46 AM
MAHON PAUL AEVP & General CounselAug 03Option Exercise57.156,000342,90041,426Aug 07 08:47 AM
ROTHBLATT MARTINE AChairman & CEOAug 03Option Exercise30.751,24838,3762,317Aug 04 05:47 PM
ROTHBLATT MARTINE AChairman & CEOAug 03Option Exercise30.7592928,567667,803Aug 04 05:47 PM
ROTHBLATT MARTINE AChairman & CEOAug 03Sale126.411,248157,7611,069Aug 04 05:47 PM
ROTHBLATT MARTINE AChairman & CEOJul 27Option Exercise30.752,17666,9122,316Jul 31 04:09 PM
ROTHBLATT MARTINE AChairman & CEOJul 27Option Exercise30.7592928,567666,874Jul 31 04:09 PM
ROTHBLATT MARTINE AChairman & CEOJul 27Sale126.401,247157,6151,069Jul 31 04:09 PM
ROTHBLATT MARTINE AChairman & CEOJul 20Option Exercise30.7594128,936665,945Jul 21 04:15 PM
ROTHBLATT MARTINE AChairman & CEOJul 20Option Exercise30.751,23638,0071,376Jul 21 04:15 PM
MAHON PAUL AEVP & General CounselJul 20Option Exercise57.156,000342,90041,426Jul 21 04:18 PM
ROTHBLATT MARTINE AChairman & CEOJul 20Sale131.621,236162,683140Jul 21 04:15 PM
ROTHBLATT MARTINE AChairman & CEOJul 13Option Exercise30.751,23838,0691,378Jul 14 04:48 PM
ROTHBLATT MARTINE AChairman & CEOJul 13Option Exercise30.7593828,844665,004Jul 14 04:48 PM
ROTHBLATT MARTINE AChairman & CEOJul 13Sale130.441,238161,486140Jul 14 04:48 PM
DWEK RAYMONDDirectorJul 06Option Exercise51.772,000103,5402,000Jul 07 04:09 PM
CAUSEY CHRISTOPHERDirectorJul 06Option Exercise54.7775041,0784,625Jul 07 04:10 PM
MAHON PAUL AEVP & General CounselJul 06Option Exercise54.746,000328,45041,426Jul 07 04:11 PM
ROTHBLATT MARTINE AChairman & CEOJul 06Option Exercise30.751,23437,9461,374Jul 07 04:12 PM
ROTHBLATT MARTINE AChairman & CEOJul 06Option Exercise30.7594328,997664,066Jul 07 04:12 PM
CAUSEY CHRISTOPHERDirectorJul 06Sale132.6159078,2403,875Jul 06 04:26 PM
ROTHBLATT MARTINE AChairman & CEOJul 06Sale132.291,234163,247140Jul 07 04:12 PM
Giltner RichardDirectorJul 05Sale131.123,490457,6090Jul 05 06:25 PM
ROTHBLATT MARTINE AChairman & CEOJun 29Option Exercise30.7593928,874663,123Jun 30 04:27 PM
ROTHBLATT MARTINE AChairman & CEOJun 29Option Exercise30.751,23738,0381,377Jun 30 04:27 PM
ROTHBLATT MARTINE AChairman & CEOJun 29Sale130.921,237161,948140Jun 30 04:27 PM
DWEK RAYMONDDirectorJun 23Sale131.713,490459,6680Jun 23 04:04 PM
ROTHBLATT MARTINE AChairman & CEOJun 22Option Exercise30.7594328,997662,184Jun 23 08:26 AM
ROTHBLATT MARTINE AChairman & CEOJun 22Option Exercise30.751,23437,9461,374Jun 23 08:26 AM
ROTHBLATT MARTINE AChairman & CEOJun 22Sale132.321,234163,282140Jun 23 08:26 AM
SULLIVAN LOUIS WDirectorJun 21Option Exercise0.001,75001,750Jun 22 04:14 PM
Giltner RichardDirectorJun 21Option Exercise0.003,49003,490Jun 22 04:13 PM
DWEK RAYMONDDirectorJun 21Option Exercise0.003,49003,490Jun 22 04:11 PM
Olian Judy D.DirectorJun 21Option Exercise0.003,49003,490Jun 22 04:12 PM
CAUSEY CHRISTOPHERDirectorJun 21Option Exercise0.003,49004,465Jun 22 04:09 PM
PATUSKY CHRISTOPHERDirectorJun 21Option Exercise0.001,75001,750Jun 22 04:10 PM
KURZWEIL RAYDirectorJun 21Option Exercise0.001,75001,750Jun 22 04:08 PM
Thompson Tommy GDirectorJun 21Option Exercise14.832,40035,6012,400Jun 22 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJun 15Option Exercise30.751,23838,0691,378Jun 19 08:21 AM
ROTHBLATT MARTINE AChairman & CEOJun 15Option Exercise30.7593828,844661,241Jun 19 08:21 AM
MAHON PAUL AEVP & General CounselJun 15Option Exercise51.376,000308,22041,426Jun 19 08:22 AM
ROTHBLATT MARTINE AChairman & CEOJun 15Sale130.201,238161,193140Jun 19 08:21 AM
ROTHBLATT MARTINE AChairman & CEOJun 08Option Exercise30.751,24038,1301,380Jun 09 08:27 AM
ROTHBLATT MARTINE AChairman & CEOJun 08Option Exercise30.7593728,813660,303Jun 09 08:27 AM
ROTHBLATT MARTINE AChairman & CEOJun 08Sale129.601,240160,699140Jun 09 08:27 AM
CAUSEY CHRISTOPHERDirectorJun 01Option Exercise54.7775041,0781,725Jun 02 04:19 PM
MAHON PAUL AEVP & General CounselJun 01Option Exercise51.376,000308,22041,426Jun 02 04:20 PM
ROTHBLATT MARTINE AChairman & CEOJun 01Option Exercise30.751,25138,4681,391Jun 02 04:22 PM
ROTHBLATT MARTINE AChairman & CEOJun 01Option Exercise30.7592528,444659,366Jun 02 04:22 PM
ROTHBLATT MARTINE AChairman & CEOJun 01Sale125.021,251156,405140Jun 02 04:22 PM
ROTHBLATT MARTINE AChairman & CEOMay 25Option Exercise30.7591228,044658,441May 26 04:04 PM
ROTHBLATT MARTINE AChairman & CEOMay 25Option Exercise30.751,26538,8991,405May 26 04:04 PM
ROTHBLATT MARTINE AChairman & CEOMay 25Sale119.401,265151,039140May 26 04:04 PM
ROTHBLATT MARTINE AChairman & CEOMay 18Option Exercise30.7591528,136657,529May 22 09:27 AM
ROTHBLATT MARTINE AChairman & CEOMay 18Option Exercise30.751,26138,7761,401May 22 09:27 AM
MAHON PAUL AEVP & General CounselMay 18Option Exercise51.376,000308,22041,426May 22 09:29 AM
ROTHBLATT MARTINE AChairman & CEOMay 18Sale120.721,261152,225140May 22 09:27 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Option Exercise30.751,25938,7141,399May 15 09:32 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Option Exercise30.7591828,229656,614May 15 09:32 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Sale122.001,259153,599140May 15 09:32 AM
MAHON PAUL AEVP & General CounselMay 04Option Exercise51.376,000308,22041,426May 05 04:07 PM
ROTHBLATT MARTINE AChairman & CEOMay 04Option Exercise30.751,25838,6841,398May 05 04:09 PM